Michael Fossel Michael is President of Telocyte

May 12, 2015

The Telomerase Revolution

My new book, The Telomerase Revolution, is now finished and is being copy edited by the publisher. Oddly enough, it’s already selling well in preorders. Amazon.com says that it is now the “#1 release in medical research”, which is a delightful surprise, since it won’t actually be published and available to the public until October. For those of you who would like to order a copy, here is the link to Amazon.com:

  • http://www.amazon.com/Telomerase-Revolution-Enzyme-Aging%C2%85-Healthier/dp/194163169X/ref=sr_1_1?ie=UTF8&qid=1426777801&sr=8-1&keywords=telomerase+revolution

The book is a careful and clear discussion of how aging works in cells, how it causes the clinical diseases of aging, and what we can do to cure age-related disease. There is a good clear chapter on vascular aging and neurodegenerative disease — especially Alzheimer’s disease — that a lot of reviewers find especially intriguing. Len Hayflick, the researcher who first described cell aging more than fifty years ago, calls the chapter “superb”. Matt Ridley, author of several best sellers including The Rational Optimist, Genome, and The Red Queen, says that he read the chapter with “real fascination” and tells me “I badly want to read more of the book”.

If anyone would like to do a book review, please contact me, and I will arrange to send you a review copy.

April 21, 2015

Biotechs on the Edge

An odd thing is happening in the world of biotechnology: an avalanche is starting.
The context is also interesting, for over the past twenty five years, a profound revolution has occurred in our understanding of aging. Where once we took aging for granted, we now reexamine the process, looking for a way to reverse it. Where once only the most avant-garde of researchers thought that perhaps we might someday learn to slow the process, now the belief that we can turn back the fundamental cellular processes has gradually become a tenet of the mainstream. Where once we looked at diet or hormones, now we look at cell aging; where once we looked at genes, we now look at epigenetics.
And where once we were pessimistic, we now see the logic behind optimism.
In my upcoming book, The Telomerase Revolution, I explain how aging works and how we can intervene to cure age-related diseases, but I also look back over the past twenty five years of biotech in aging research. Oddly enough, in every single case, the failures have not been due to flawed science, but to flawed human beings. Poor decisions, paranoia, an inability to believe one’s own data, distrust, poor public relations, bad business ethics, these are all the failures of flawed human beings, unable to avoid shooting themselves in the foot — often fatally, which is an extremely odd anatomic result, but there it is. Biotech death by foolish behavior.
And yet the science was solid.
So perhaps it’s not surprising that I finally see a new generation of biotech startups, all aimed at the holy grail of age-related disease: resetting gene expression in aging cells and thereby curing age-related disease. Perhaps it was due to the gradual growth of inescapable data, as mice and rats in Boston and Madrid have driven home the point that aging can be altered and that diseases can be reversed. Perhaps it was the coming-of-age of a generation who, when asked to explain aging, began their answers with a short explanation about telomeres and aging cells. Or perhaps it was simply about time that we got things right.
Whatever the reason, the avalanche is beginning. I see investors, lay people, entrepreneurs, and businessmen moving steadily to support biotech ventures aimed directly at resetting gene expression, resetting cell aging, resetting age-related disease, and doing what was assumed to be impossible a mere generation ago.
It’s an avalanche that — by 2020 — will demonstrate that we can not only commiserate about Alzheimer’s disease, but we can cure it. In most cases, we will not merely slow the diseases of aging, not merely fight them to a grudging standstill, but reverse their pathology. None of our current therapies for vascular disease, osteoporosis, osteoarthritis, or (least of all) Alzheimer’s disease are “disease modifying”. Our current therapies offer little solace and no hope of cure, yet a cure is precisely what the newest crop of biotechnology companies are pursuing. Of the growing number of biotechnology companies now on the edge of success, some will fail, but the avalanche is already heading down the mountain and it’s gathering speed.
It won’t stop until we get to the bottom of age-related disease.

« Newer Posts

Powered by WordPress